LSTA Lisata Therapeutics, Inc.
USHealthcareAs of 2026-07-10 14:18
Why LSTA matters now
Lisata Therapeutics, Inc. (LSTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.30 with +2.01% on the session and $30.1M in market capitalization; recent performance reads 1-month +12.82% and YTD +89.25%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.5M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -42.6%.
The latest indexable market news headline is "Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes AZAB MOHAMMAD filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.90
P/S
188.56
EV/EBITDA
-1.14
DCF Value
$1.92
FCF Yield
-42.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.8%
Operating Margin
-10178.2%
Net Margin
-9618.2%
ROE
-101.9%
ROA
-116.3%
ROIC
-157.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.5M | $-0.50 |
| Q4 2025 | $100.0K | $-3.0M | $-0.33 |
| FY 2025 | $170.0K | $-16.6M | $-1.91 |
| Q3 2025 | $0.00 | $-4.2M | $-0.49 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.81
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.